Shots:
- Health Canada has approved Columvi + GemOx for the treatment of ASCT-ineligible pts with r/r diffuse large b-cell lymphoma (DLBCL)
- Approval was based on P-III (STARGLO) study of Columvi + GemOx vs MabThera/Rituxan + GemOx for r/r DLBCL
- At mFU of 11.3mos., the trial met its 1EP of OS, reducing the death risk by 41%, along with its 2EP of improved PFS by 63% while at mFU of 20.7mos., Columvi regimen showed mOS of 25.5 vs 12.9mos., with 58.5% vs 25.3% pts experiencing CR
Ref: Newswire.CA| Image: Roche| Press Release
Related News:- Roche Reports P-III (Portal) Trial Data on Susvimo for Neovascular Age-Related Macular Degeneration (nAMD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
